Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas.
We retrospectively analyzed clinical presentation, immunopathological data and renal outcome in 13 patients with glomerulonephritis (GN) and chronic lymphocytic leukemia (CLL) or related diffuse well-differentiated lymphocytic lymphoma (WDLL) of B-cell lineage. B-cell proliferation and glomerulopathy were simultaneously diagnosed in seven of the 13 patients. Nephrotic syndrome was observed in nine patients. Serum creatinine was elevated (greater than 120 mumol/liter) in 10 patients and exceeded 400 mumol/liter in three patients. A clear cut relationship between GN and hematologic disease could be established in nine cases: five patients had MPGN caused by type I or type II cryoglobulinemia; two had MPGN or mesangial hypertrophy with circulating and deposited noncryoprecipitating monoclonal IgG K and IgM K, respectively; in the two remaining patients, monotypic IgG K glomerular deposits exhibiting fibrillary organization were observed in association with MGN or MPGN, despite the absence of circulating M-component by immunofixation. The pathophysiologic link between glomerular lesions and B-cell proliferation was further evidenced by effectiveness of specific treatment of the malignancy by chlorambucil. This drug, used in the absence of steroids, induced complete remission of nephrotic syndrome in the five patients to whom it was given. Moreover, in the five patients with creatininemia greater than 200 mumol/liter who received chemotherapy, substantial improvement in renal function was observed. These overall data demonstrate that the occurrence of GN in B-CLL and related lymphoma is not fortuitous, and testify to the paraneoplastic nature of glomerular involvement mediated by deposition and possibly processing of cryoprecipitating or noncryoprecipitating M-components.
Moulin
B
B
Department of Nephrology, CHU Rouen, Paris, France.
Ronco
P M
PM
Mougenot
B
B
Francois
A
A
Fillastre
J P
JP
Mignon
F
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000276:immunology; D002699:Chlorambucil / Q000627:therapeutic use; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy / Q000209:etiology; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000097:blood; D007136:Immunoglobulins / Q000097:blood; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications*; D008213:Lymphocyte Activation; D016393:Lymphoma, B-Cell / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000209:etiology
D007145:Immunoglobulin kappa-Chains; D007136:Immunoglobulins; D002699:Chlorambucil